← All stories
Health, Longevity & Biohacking

Dr Chris Thompson says many patients discontinue GLP-1 drugs within a year

By Egleze Editorial Desk · Published September 23, 2026 · Huberman Lab · Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson
Dr Chris Thompson says many patients discontinue GLP-1 drugs within a year
Huberman Lab
Huberman Lab
Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson

What was said

""About 30% come off GLP-1s in the first month and then 50% or so by by the end of the year, right?""

Dr Chris Thompson, a Harvard Medical School professor and interventional gastroenterologist, says adherence to GLP-1 medicines is a challenge and claims around 30% of users stop within the first month and roughly half stop by the end of the first year. He says the pattern resembles drop-off seen with other long-term medicines and discusses potential drivers including nausea during dose escalation, injection “needle fatigue” and uncertainty about long-term effects.

Verification status

Attributed speaker claim

Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.

Source and context

Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.

Speaker
Dr. Chris Thompson · guest
Programme
Huberman Lab
Episode
Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson
Clip time
31:22
Original source
Watch the source segment →
From this episode
Huberman Lab
Huberman Lab

Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson

September 21, 2026 · 2h 27m · 7 Egleze moments
Read episode summary and key points →

More moments from this episode

Health, Longevity & BiohackingDr Chris Thompson recalls fistula closure after bypass linked to diabetes improvement→Health, Longevity & BiohackingDr Chris Thompson says Whitehall II links fasting insulin to earlier diabetes risk→Health, Longevity & BiohackingDr Chris Thompson claims duodenal ablation can cut HbA1c by over a point→Health, Longevity & BiohackingDr Chris Thompson describes patients ‘micro-dosing’ GLP-1s by decanting pen doses into vials→
More stories More from Huberman Lab